The Pharmaceutical Research and Manufacturers of America’s new ASAP 340B coalition “is another misguided attempt by drug companies to dismantle the 340B Drug Pricing Program so that they can continue to pad their billion-dollar bottom lines,” writes Bharath Krishnamurthy, director of health analytics and policy for the AHA. “The self-serving policy proposals outlined by this new alliance directly contravene Congress’ oft-demonstrated intent to preserve the 340B program over the last 30 years. Those most impacted by this coalition’s assault on 340B are the millions of patients who will lose access to lifesaving medicines and to other vital health care services supported by the program.” READ MORE

Related News Articles

Perspective
With only 11 days that the House and Senate are in session together before the fiscal year concludes, much of the attention in Washington is on how Congress…
Headline
The Centers for Medicare & Medicaid Services has extended to Sept. 11 the deadline to submit comments on its proposed remedy for the unlawful payment…
Headline
AHA urged the House Energy and Commerce Committee to consider including in its draft legislation to address drug shortages legislative proposals that would…
Headline
The AHA filed its comment letter on the Department of Health and Human Services’ proposed remedy for the unlawful payment cuts to certain hospitals that…
Headline
A Modern Healthcare analysis of 340B hospitals “should be viewed with the derision it deserves,” writes AHA General Counsel and Secretary Melinda Hatton. “It…
Blog
Modern Healthcare’s putative report on CMS’ 340B remedy proposal is completely wrong and irresponsible for the following reasons. First, to reach its…